EFB Dengue Literature Review

CD19

6 min read

CD19

Overview

CD19 is a type I transmembrane glycoprotein and co-receptor of the B cell receptor complex, expressed broadly on all B lineage cells from pro-B through mature B cells and lost upon terminal differentiation to plasma cells. It is the standard pan-B cell gate in flow cytometry panels; B cell subsets are conventionally defined as percentages of CD19⁺ cells.

Key Points from Literature

  • All B cell subset analyses in Wei et al. are gated on live CD19⁺ lymphocytes; percentages of naive, memory, DN, and plasma cells are reported as fractions of CD19⁺ PBL (see Wei2007 - DN Memory B Cells in SLE).

  • CD19 expression is used together with CD20 for FACS sorting of B cells for BCR sequencing: CD19⁺CD20⁺IgG⁺IgD⁻ cells were sorted into CD27⁺ and CD27⁻ fractions (see Wei2007 - DN Memory B Cells in SLE).

  • CD19^low as a plasmablast identifier: Plasmablasts downregulate CD19 upon terminal differentiation. In the combined gate CD38^high, CD19^low, CD20⁻, the CD19^low criterion helps exclude pre-GC cells (which remain CD19^bright). CD19 downregulation tracks with CD20 loss as B cells differentiate into antibody-secreting cells (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • CD19^hi marks activated naive (acN) B cells: In contrast to the downregulation seen at the plasmablast stage, B cell activation upregulates CD19 surface expression. Within the IgD⁺CD27⁻ naive compartment, the CD19^hi fraction is dramatically enriched for activated (MTG⁺CD24⁻) acN cells in SLE flares, and these CD19^hi cells are selectively enriched for autoreactive 9G4⁺ B cells relative to the CD19⁺ resting fraction. CD19^hi expression tracks with CD21 downregulation upon activation (see Tipton2015 - ASC Diversity and Origin in SLE, citing Masilamani et al. 2003 and Wehr et al. 2004).

  • CD19^hi is a defining DN2 marker: DN2 B cells (IgD⁻CD27⁻CXCR5⁻CD21⁻CD11c⁺) express CD19 at a characteristically high level — the same CD19^hi expression shared with aNAV cells. CD19^hi is one of the markers that distinguishes DN2 from DN1 (CD19 intermediate). In the EF differentiation pathway (rNAV → aNAV → DN2), CD19^hi expression is acquired at the aNAV stage and retained through DN2. RNA-seq confirms that CD19 upregulation in DN2/aNAV is part of the broader activation programme (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, flow cytometry + RNA-seq).

  • CD19⁺ as primary B cell gate in dengue plasmablast studies: In Wrammert2012, plasmablasts are gated as CD19⁺CD3⁻CD20⁻/low CD27^high CD38^high on an extended lymphocyte gate (to capture blasting cells). CD19⁺ is the anchor gate; plasmablast frequencies reported as percentage of CD19⁺ B cells (average 47% in acute dengue). This is the simplest dengue plasmablast panel in the wiki (5-color) and confirms CD19 as the universal B cell denominator across all dengue panels (see Wrammert2012 - Plasmablast Responses in Acute Dengue, 5-color conventional FCM).

  • CD19⁺ gate for both PB and MBC sorting in dengue clonal analysis: Appanna2016 used CD19⁺ as the anchor for both plasmablast sorting (CD19⁺CD20⁻CD27^hiCD38^hi) and DENV-specific MBC sorting (CD19⁺CD20⁺CD27⁺), confirming CD19 as the universal B cell gate across all dengue B cell studies. 0.1–19% of total lymphocytes were CD19⁺ plasmablasts; 0.5–8.1% of CD19⁺CD20⁺ B cells bound DENV (see Appanna2016 - Plasmablasts as Subset of Memory B Cell Pool, FACSAria, n=12 dengue).

  • B220⁺CD19⁺ was the shared pan-B anchor gate in both founding murine ABC definitions (Hao et al. 2011 and Rubtsov et al. 2011), with the two schemes then diverging on which additional markers (loss of CD21/CD23/CD95/CD43 vs. gain of CD11c) defined the ABC subset within that gate (see Cancro2020 - Age-Associated B Cells, review — no original data; mouse).

  • CD19 is core marker (2) of the recommended seven, and is preferred over CD20 when the panel is tight. The nomenclature review argues CD19 should be chosen over CD20 where markers are limited, because CD19 staining intensity itself carries activation information and helps separate short-lived from long-lived plasma cells; CD20 is then added back only for extra ASC-discriminating power. In vitro, the ABC-inducing condition (TLR7 + IFN + IL-21) produces a CD19++ CD21ˡᵒCD11c⁺⁺T-bet⁺⁺FcRL5⁺ phenotype — so CD19 brightness is itself part of the activated-effector signature, not a fixed lineage constant (see Sanz2019 - Consistent Classification of Human B Cell Populations, review — no original data).

  • [2026-08-29] CD19⁺CD3⁻ as the parent gate and the reporting denominator at cohort scale. All subset frequencies in a 207-patient lupus-spectrum study — DN1/DN2/DN3, activated naive and transitional T1+T2 — were expressed as a percentage of CD19⁺ cells, with activated naive additionally reported as a proportion of total naive (see Jenks2021 - B Cell Subset Composition in Cutaneous Lupus, n=207 + 46 healthy controls, cross-sectional, conventional flow). Consistent denominator reporting is what makes the five-cluster fingerprint comparable across subjects.

  • CD19^hi^ is a reported discriminator of DN2 from DN1 in SLE blood. Patient DN2 cells uniformly expressed high CD19 along with high T-bet and FcRL5, whereas DN1 cells did not; CD19^hi/lo^ was also used as a gating dimension in the in vitro cultures (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human, n=20 HD + n=40 SLE + in vitro reconstruction). Worth noting for panel design: CD19 is usually treated purely as a lineage marker, but its intensity carries subset information within the DN gate here.

  • CD19 is retained while CD20 is lost during de novo plasmablast differentiation — a stage-related counterpoint to the CD19^low gate above. Resting B cells were isolated with CD19 magnetic beads (Miltenyi, ≥95% purity) and, after 6 days of coculture with DENV-infected monocytes, the dividing (CFSE-diluted) cells “expressed CD19 and downregulated CD20, characteristic of differentiating plasmablasts” (see Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue, in vitro, 4 independent experiments with 4 healthy blood donors). This does not conflict with the CD19^low plasmablast criterion from Anolik2004 - Rituximab and B Cell Abnormalities in SLE: those are mature circulating plasmablasts, these are day-6 differentiating cells, and Kwissa scores CD19 qualitatively (positive vs negative) rather than by intensity — so the CD19^low rule is untested here rather than contradicted.

Contradictions & Debates

None documented in current wiki sources.

CD20, CD38, Activated Naive B Cell, DN2 B Cell, Conventional Flow Cytometry, Double-Negative B Cell, Memory B Cell, Plasmablast

Sources

Graph View

Backlinks